Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Non-Current Receivables (2021 - 2024)

Summit Therapeutics' Non-Current Receivables history spans 4 years, with the latest figure at $698000.0 for Q4 2024.

  • For Q4 2024, Non-Current Receivables fell 27.22% year-over-year to $698000.0; the TTM value through Dec 2024 reached $698000.0, down 27.22%, while the annual FY2024 figure was $698000.0, 27.22% down from the prior year.
  • Non-Current Receivables reached $698000.0 in Q4 2024 per SMMT's latest filing, up from $467000.0 in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $11.3 million in Q3 2021 to a low of $212000.0 in Q1 2024.
  • Average Non-Current Receivables over 4 years is $2.4 million, with a median of $747000.0 recorded in 2023.
  • Peak YoY movement for Non-Current Receivables: plummeted 77.92% in 2023, then fell 27.22% in 2024.
  • A 4-year view of Non-Current Receivables shows it stood at $11.3 million in 2021, then crashed by 70.79% to $3.3 million in 2022, then crashed by 70.95% to $959000.0 in 2023, then dropped by 27.22% to $698000.0 in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Non-Current Receivables are $698000.0 (Q4 2024), $467000.0 (Q3 2024), and $364000.0 (Q2 2024).